TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
61.18
+3.10 (5.34%)
At close: Oct 30, 2026, 4:00 PM EDT
61.65
+0.47 (0.77%)
After-hours: Oct 30, 2026, 7:53 PM EDT
TG Therapeutics Employees
TG Therapeutics had 399 employees as of December 31, 2025. The number of employees increased by 61 or 18.05% compared to the previous year. That makes TG Therapeutics the 21,809th largest employer in the world and 2,852nd in the United States.
Employees
399
Change (1Y)
61
Growth (1Y)
18.05%
Revenue / Employee
$2,003,850
Profits / Employee
$1,106,491
Market Cap
8.68B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 399 | 61 | 18.05% |
| Sep 30, 2025 | 374 | 55 | 17.24% |
| Jun 30, 2025 | 370 | 70 | 23.33% |
| Mar 31, 2025 | 352 | 68 | 23.94% |
| Dec 31, 2024 | 338 | 74 | 28.03% |
| Sep 30, 2024 | 319 | 74 | 30.20% |
| Jun 30, 2024 | 300 | 56 | 22.95% |
| Mar 31, 2024 | 284 | 47 | 19.83% |
| Dec 31, 2023 | 264 | 38 | 16.81% |
| Sep 30, 2023 | 245 | 59 | 31.72% |
| Jun 30, 2023 | 244 | 71 | 41.04% |
| Mar 31, 2023 | 237 | 18 | 8.22% |
| Dec 31, 2022 | 226 | -60 | -20.98% |
| Sep 30, 2022 | 186 | -179 | -49.04% |
| Jun 30, 2022 | 173 | -155 | -47.26% |
| Mar 31, 2022 | 219 | -82 | -27.24% |
| Dec 31, 2021 | 286 | 14 | 5.15% |
| Sep 30, 2021 | 365 | 148 | 68.20% |
| Jun 30, 2021 | 328 | 152 | 86.36% |
| Mar 31, 2021 | 301 | 148 | 96.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Twist Bioscience | 979 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Praxis Precision Medicines | 168 |
TGTX News
- 9 days ago - TG Therapeutics announces Phase 1 data evaluating azer-cel in MS - TheFly
- 9 days ago - TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 - Business Wire
- 11 days ago - TG Therapeutics highlights data across MS portfolio at MSToronto2026 - TheFly
- 11 days ago - TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026 - Business Wire
- 20 days ago - TG Therapeutics announces publication of five-year analysis of BRIUMVI - TheFly
- 20 days ago - TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis - Business Wire
- 24 days ago - TG Therapeutics to present data on azer-cel at MSToronto2026 - TheFly
- 24 days ago - TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 - Business Wire